CNCMT:a Multi-center, Prospective, Single-arm Study

NAEnrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Locally Advanced Cervical CancerPD1CTLA4
Interventions
DRUG

Neoadjuvant Chemotherapy (NACT)

Two cycles of carbonilumab plus TP regimen neoadjuvant chemotherapy will be implemented to patients with advanced cervical cancer

DRUG

maintenance therapy

one years of maintenance therapy with carbonilumab alone will be implemented to patients with advanced cervical cancer receiving standard concurrent chemoradiotherapy

Trial Locations (1)

430079

Hubei Cancer Hospital, Wuhan

Sponsors
All Listed Sponsors
collaborator

Yichang Central People's Hospital

OTHER

collaborator

Akeso Pharmaceuticals, Inc.

OTHER

lead

Hubei Cancer Hospital

OTHER